Overview:

Cyclosporine functions as a central immunosuppressive drug which physicians use for treating both organ transplant patients and persons suffering from rheumatoid arthritis and other autoimmune diseases.Pharmaceutical formulations commonly use the 11-amino acid cyclic polypeptide which scientists derived from Beauveria nivea fungus.The therapeutic drug enhances immune regulation which enables transplant defense while reducing autoimmune pathology inflammation.The United States Food and Drug Administration approved Cyclosporine in January 2000.

What Is Cyclosporine Used For?

Cyclosporine is primarily used to suppress the immune system in several medical conditions:

Organ Transplantation: Prevents organ rejection in recipients of kidney, liver, or heart transplants.
Autoimmune Disorders: Helps manage conditions like rheumatoid arthritis, psoriasis, and severe atopic dermatitis.
Other Uses: It may also be prescribed for nephrotic syndrome and refractory cases of inflammatory bowel diseases like Crohn’s disease and ulcerative colitis.

Drug Group:

Cyclosporine belongs to the drug class known as immunosuppressants. These drugs suppress the immune system and are frequently employed to inhibit the rejection of newly transplanted organs and for certain autoimmune diseases.

Indications:

Cyclosporine capsules are used for various medical conditions to suppress the immune system.

Here are some common indications for the use of Cyclosporine capsules:

Organ Transplantation: Prevention of rejection in organ transplant recipients (for example, kidney, liver, heart).
Autoimmune Diseases: Treatment of autoimmune disorders such as rheumatoid arthritis (affects joints, causing inflammation and potential deformities) and psoriasis (leads to skin plaques and can involve joints).
Atopic Dermatitis (Eczema): Management of severe cases of atopic dermatitis (eczema) when other treatments are ineffective.
Graft-versus-Host Disease (GVHD): The prevention and treatment of graft-versus-host disease can occur after bone marrow or stem cell transplantation.
Nephrotic Syndrome: Treatment of nephrotic syndrome, a kidney disorder characterized by proteinuria (proteins in the blood) and edema (swelling).
Inflammatory Bowel Disease: In some cases, Cyclosporine may be used for severe or refractory inflammatory bowel diseases like Crohn's disease (which impacts any part of the gastrointestinal [GI] tract) and ulcerative colitis (which affects the colon and rectum).

Cyclosporine Dosage and Forms

Dosage Forms

Cyclosporine is available in capsule form, with strengths of 25 mg and 100 mg. The medication is also available as oral solutions and injections for specific cases.

Typical Dosages

Organ Transplantation: Initial doses range from 8–12 mg/kg/day, divided into two doses, with gradual reduction.
Autoimmune Conditions: Maintenance doses often start at 2.5–5 mg/kg/day, adjusted based on therapeutic response and side effects.

For Patients:

How Do Cyclosporine Capsules Work?

Cyclosporine capsules are a part of the cyclosporine drug class, they are known as immunosuppressive agents. These drugs primarily work by suppressing the immune system. Cyclosporine specifically inhibits the activity of certain immune cells, particularly T-cells, which play a vital role in the immune response. By modulating T-cell activity, Cyclosporine helps reduce the immune system's overall response.

Cyclosporine Uses in Transplantation: For transplant recipients, The immune system might see the transplanted organ as a threat and try to attack or reject it.
Cyclosporine Mechanism and Interactions:. Patients should be aware of cyclosporine interactions, especially with grapefruit products, antibiotics, and antifungals, as these can alter drug levels in the bloodstream and potentially lead to cyclosporine toxicity.
Monitoring and Risks: While effective, Cyclosporine requires careful monitoring due to its potential for cyclosporine toxicity, which can impact kidney function, blood pressure, and other systems. Regular health checks, including blood tests and kidney function evaluations, are critical for the safe and effective use of this medication.

What Should I Know About Cyclosporine Before Taking It?

Medical History and Precautions:

Pre-existing Conditions: Inform your healthcare provider if you have kidney disease, hypertension, liver issues, or a history of cancer.
Drug Interactions: Cyclosporine has significant interactions with many drugs, including antifungal agents, antibiotics, and NSAIDs, as well as certain foods like grapefruit, which can alter its metabolism.
Vaccinations: Avoid live vaccines during treatment, as Cyclosporine suppresses the immune response.

Routine Monitoring

Kidney Function Tests: Since cyclosporine toxicity often affects the kidneys, regular monitoring is critical.
Blood Pressure: Hypertension is a common side effect requiring management.

What Is the Dosage of Cyclosporine Capsules?

The dosage is as follows:

Organ Transplantation:

To prevent rejection in individuals who have undergone transplantation, the initial dosage is often higher and is gradually reduced over time.
Typical starting doses might be around eight to 12 mg/kg (milligrams per kilogram of body weight) per day, divided into two doses.

Autoimmune Conditions (Rheumatoid Arthritis and Psoriasis):

Lower maintenance doses are often used for the treatment of autoimmune conditions.
Dosages may start at around 2.5 to 5 mg/kg daily, divided into two doses.

How Effective Is Cyclosporine Capsules?

Cyclosporine is an immunosuppressive medication used for conditions like severe psoriasis or, less commonly, rheumatoid arthritis.

What Are the Things to Inform the Doctor Before Taking Cyclosporine Capsules?

Before starting Cyclosporine capsules, informing the doctor about various aspects of health is crucial to ensuring safe and effective use. Here are key things to discuss with the healthcare provider:

Medical History: Inform the doctor about any pre-existing medical conditions one may have, especially kidney disease, high blood pressure, liver disease, infections, or a history of cancer.
Current Medications: Give a complete list of all the medicines the patient is taking, whether they are prescribed or bought without a prescription, including vitamins and supplements that the patient is currently taking, as well as any herbal supplements or alternative therapies.
Pregnancy and Breastfeeding: Inform about pregnancy, planning to become pregnant, or breastfeeding. Cyclosporine may have potential risks during pregnancy.
Vaccinations: Update the doctor on any recent vaccinations or plans for vaccination, as Cyclosporine may affect one’s response to certain vaccines.
Infections: Report any current or recent infections to the doctor. Cyclosporine can suppress the immune system, and infections may need to be treated before starting the medication.
Allergies: Inform the doctor about any allergies, especially if the patient has had allergic reactions to Cyclosporine or other medications.
Previous Medication Use: If one has previously used immunosuppressive medications, share that information with the doctor.
Smoking and Alcohol Use: Inform the doctor about smoking and alcohol habits, as these factors may influence the choice of treatment.

How Are Cyclosporine Capsules Administered?

Cyclosporine capsules should be administered twice daily on a consistent schedule, irrespective of meals. Avoiding grapefruit or grapefruit juice is recommended, as it can affect the metabolism of Cyclosporine, leading to increased blood concentrations.

What Are the Side Effects of Cyclosporine Capsules?

The side effects are as follows:

Kidney, Liver, and Heart Transplantation:

Adverse reactions to Cyclosporine therapy include renal dysfunction (impaired kidney function), tremors (involuntary shaking or trembling of hands, limbs, or other body parts), hirsutism (abnormal and excessive hair growth), hypertension (high blood pressure), and gum hyperplasia (overgrowth of gum tissue).
Hypertension occurs in about 50 percent of renal transplant patients and most cardiac transplant patients.
Glomerular capillary thrombosis (blood clot formation in the tiny vessels of the kidney) and hypomagnesemia (low magnesium levels).
Infections and postmarketing experiences highlight hepatotoxicity (liver toxicity), increased infection risk, and neurological complications.

Rheumatoid Arthritis:

Dietary Considerations:

Maintain a consistent schedule for taking the capsules concerning meals. Ensure a balanced diet as well.

Missed Dose:

If you miss a dose of Cyclosporine capsules, take it as soon as you remember. If you’re unsure or have concerns about missed doses, don't hesitate to contact your healthcare provider.

Overdose:

An overdose of Cyclosporin can cause serious symptoms such as nausea, vomiting, seizures, and kidney problems. It's important to seek immediate medical help if this occurs. Gastric lavage and activated charcoal may be employed to remove unabsorbed Cyclosporin. Symptomatic treatment addresses specific manifestations while adjusting or discontinuing Cyclosporin, which helps reduce blood concentrations.

Monitoring vital signs and organ function closely is important, and supportive care is provided as needed. In severe cases, hemodialysis (a medical procedure for filtering blood to remove waste and excess fluids when the kidneys cannot perform this function effectively) may be considered to enhance Cyclosporin removal. Seeking professional medical assistance is imperative for the appropriate evaluation and management of Cyclosporin overdose.

Storage

It is necessary to keep and distribute from the original single-dose container at a controlled room temperature of 68 degrees Fahrenheit to 77 degrees Fahrenheit (20 degrees Celsius to 25 degrees Celsius).

For Doctors:

Chemical Composition:

Cyclosporine is denoted as cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-α-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl).

Dose:

Dosing Guidelines for Organ Transplantation in Adults:

Oral Administration:

Four to 12 Hours Before the Transplant: Take a single oral dose of 14 to 18 mg/kg.
One to Two Weeks After the Transplant: Take 5 to 15 mg/kg per day orally, divided into two doses.
Gradual Reduction: Decrease the dose by five percent each week until reaching 5 to 10 mg/kg per day orally, divided into two doses.

Focal Segmental Glomerulosclerosis: The recommended oral dosage is 3 mg/kg daily, administered every 12 hours.

Rheumatoid Arthritis: For the oral (modified) form, start with a dose of 2.5 mg/kg daily, taken every 12 hours. If there is an inadequate response after eight weeks, consider increasing the dosage by 0.5 to 0.75 mg/kg daily. The daily dosage should not exceed 4 mg/kg.

Psoriasis: In the case of the oral (modified) formulation, start with an initial dosage of 2.5 mg/kg per day, administered every 12 hours. If the desired response is not achieved after four weeks, an incremental increase of 0.5 mg/kg per day may be considered. The maximum recommended daily dose is 4 mg/kg.

Dosing Considerations:

Renal Impairment: Cyclosporine's pharmacokinetics are minimally affected by routine hemodialysis in end-stage renal disease. Due to its nephrotoxic potential, renal function should be closely monitored, and dosage should be adjusted if needed. Patients with impaired renal function, rheumatoid arthritis, or psoriasis should avoid Cyclosporine.
Hepatic Impairment: Severe liver disease may reduce Cyclosporine clearance, requiring dose adjustments to maintain recommended blood concentrations.
Newly Transplanted Patients: Cyclosporine's initial dose depends on the transplanted organ. Dosage adjustments are based on blood concentrations. Adrenal Corticosteroids are recommended initially, with gradual tapering.

What Are the Pharmacological Aspects of Cyclosporine Capsules?

Pharmacodynamics

Cyclosporine serves as a potent immunosuppressive agent, effectively prolonging the survival of allogeneic transplants in animals, encompassing various organs such as skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lungs.
Demonstrated effects of Cyclosporine include suppressing the inhibition of humoral immunity and, to a greater degree, cellular immune responses. These reactions encompass allograft rejection, delayed hypersensitivity, experimental allergic encephalomyelitis, Freud’s adjuvant arthritis, and graft versus host disease across numerous animal species and organ types.
Cyclosporine's effectiveness arises from its targeted and reversible blocking of immunocompetent lymphocytes during the G0 and G1 phases of the cell cycle, with a preferential focus on T-lymphocytes. The primary target is the T-helper cell, although the T-suppressor cell may also be affected. Additionally, Cyclosporine inhibits the production and release of lymphokines, including interleukin-2.
Importantly, no discernible effects on phagocytic function, such as changes in enzyme secretions, chemotactic migration of granulocytes, macrophage migration, or carbon clearance in vivo, have been observed in animals. Furthermore, Cyclosporine does not induce bone marrow suppression in animal models or humans.

Mechanism

T-Cell Activation Blockade:

Inhibition of Calcineurin hinders the activation of T-cells.
T-cells have a central role in the immune response.

Cytokine Production Reduction:

T-cell activation usually leads to cytokine production, essential for immune responses.
Cyclosporin's action results in reduced cytokine production, such as interleukin-2.

Suppression of Immune Response:

With decreased cytokine production, there is suppression of the immune response.
This is particularly valuable in preventing rejection of transplanted organs and treating autoimmune diseases.

Pharmacokinetics

Absorption: The immunosuppressive effect of Cyclosporine is primarily attributed to the parent drug. Upon oral administration, the absorption of Cyclosporine is incomplete. The degree of absorption is subject to variability among individual patients, the patient population, and the specific formulation.
Elimination: Cyclosporine is predominantly eliminated through biliary pathways, with only six percent of the administered dose (comprising both the parent drug and metabolites) excreted in urine.
Disposition: The elimination of Cyclosporine from the bloodstream typically follows a biphasic pattern, with a terminal half-life of approximately 8.4 hours (range: five to 18 hours). After intravenous administration, blood clearance of Cyclosporine ranges from approximately five to seven mL/min/kg (milliliters per minute per kilogram of body weight) in adult recipients of renal or liver allografts. Cardiac transplant patients may exhibit slightly slower blood clearance.
Bioequivalence: The impact of milk on the bioavailability of Cyclosporine when administered as Cyclosporine has not been assessed.
Dose-Exposure Relationship: The relationship between the administered dose and exposure is linear within the therapeutic dose range.

Toxicity:

In cases of toxicity, priority should be given to establishing a clear airway.

Hemodialysis, a medical procedure that filters and cleanses the blood outside the body, is typically used for kidney failure; it eliminates only one percent of the dose. Monitoring serum CsA (Cyclosporine A levels) levels is mandatory, with the potential for multiple dose adjustments during treatment. The CVC (central venous catheter line) line is not used to infuse CsA. Still, it can safely collect blood samples for serum CsA levels, following proper techniques for discarding five mL of blood immediately after interrupting the infusion.

Clinical Studies:

The efficacy of Cyclosporin capsules in addressing severe rheumatoid arthritis was assessed through five clinical studies, encompassing 728 patients treated with Cyclosporine and 273 patients on a placebo. The responder rates per treatment group are summarized, where a responder is defined as a patient completing the trial with a 20 percent improvement in both tender and swollen joint counts and a 20 percent improvement in two of four specified criteria.

In Study 651, 264 patients with active rheumatoid arthritis were enrolled and randomized into three groups:

Cyclosporine at 2.5 to 5 mg/kg/day.
Methotrexate at 7.5 to 15 mg/week.
Placebo.

The treatment duration was 24 weeks, and at the final visit, the average Cyclosporine dosage was 3.1 mg/kg/day.

Study 652 involved 250 patients with active rheumatoid arthritis, randomizing them into three treatment arms:

1.5 to 5 mg/kg/day of Cyclosporine.
2.5 to 5 mg/kg/day of Cyclosporine.
Placebo.

The treatment duration was 16 weeks, and at the last visit, the average Cyclosporine dosage for Group 2 was 2.92 mg/kg/day.

In Study 2008, 144 patients with active rheumatoid arthritis were enrolled and randomized into two groups.

Cyclosporine was administered at 2.5 to 5 mg/kg/day with adjustments to reach a target trough level.
Placebo.

The treatment duration was 24 weeks, and at the final visit, the average Cyclosporine dosage was 3.63 mg/kg/day.

Study 654 included 148 patients with active joint counts of 6 or more despite maximally tolerated methotrexate doses. Patients were randomized to receive either.

Cyclosporine 2.5 mg/kg/day with dose adjustments.
Placebo, in addition to the current Methotrexate dose.

The treatment duration was 24 weeks, and the mean Cyclosporine dose at the last visit was 2.8 mg/kg/day.

What Are the Contraindications of Cyclosporine Capsules?

The contraindications are as follows:

Cyclosporine capsules are not recommended for individuals with hypersensitivity to Cyclosporine or any of the components in the formulation.
Patients with rheumatoid arthritis with abnormal kidney function, uncontrolled hypertension, or malignancies should refrain from using Cyclosporine capsules.
Psoriasis patients undergoing Cyclosporine capsule treatment should refrain from concurrent use of PUVA or UVB therapy, Methotrexate, other immunosuppressive agents, coal tar, or radiation therapy. Additionally, individuals with psoriasis and abnormal renal function, uncontrolled hypertension, or malignancies are advised against receiving Cyclosporine capsules.

Warnings and Precautions: The following are the warnings associated with:

1. All Patients: Cyclosporine has the potential to induce nephrotoxicity and hepatotoxicity, with the risk escalating with higher Cyclosporine doses.

Patients receiving Cyclosporine require frequent monitoring of serum creatinine levels, especially in the elderly, as age-related decrease in renal function may occur. Inadequate monitoring and improper dose adjustments may lead to structural kidney damage and persistent renal dysfunction.

During Cyclosporine therapy, an increase in serum creatinine and BUN (blood urea nitrogen) may occur, reflecting a decrease in the glomerular filtration rate. Structural kidney damage and persistent renal dysfunction may ensue without proper dose reduction or discontinuation.

2. Kidney, Liver, and Heart Transplant

Nephrotoxicity: Cyclosporine can induce nephrotoxicity and hepatotoxicity at higher doses, leading to elevated serum creatinine and BUN levels. The increased levels in patients with renal transplants do not necessarily suggest rejection and a thorough patient evaluation is essential before initiating dosage adjustments. Based on historical Cyclosporine experience, nephrotoxicity associated with Cyclosporine was noted in 25 percent of renal transplant cases, 38 percent of cardiac transplant cases, and 37 percent of liver transplant cases. Mild nephrotoxicity typically occurs two to three months post-renal transplant, with manifestations such as a plateau in pre-operative BUN and creatinine elevations.
Nephrotoxicity vs. Rejection: Several parameters may help distinguish nephrotoxicity from rejection, but up to 20 percent of patients may experience simultaneous nephrotoxicity and rejection. Careful monitoring and frequent dosage adjustments may be necessary in cases of impaired renal function. A form of Cyclosporine-associated nephropathy, characterized by a progressive deterioration in renal function and morphological changes, may occur in 5 to 15 percent of transplant recipients. This condition may persist despite decreasing or discontinuing Cyclosporine therapy and requires evidence from renal biopsies for diagnosis. The reversibility of interstitial fibrosis and its correlation with renal function remains undetermined. While arteriolopathy reversibility has been reported, caution is advised to avoid excessive immunosuppression, especially in severe and unremitting rejection episodes.

3. Thrombotic Microangiopathy: Detection and management of this syndrome involve platelet studies and early intervention, including streptokinase, heparin, or plasmapheresis.

4. Hyperkalemia: Individual patients have occasionally experienced notable hyperkalemia, sometimes linked with hyperchloremic metabolic acidosis and hyperuricemia.

5. Hepatotoxicity: Hepatotoxicity, manifesting as elevated hepatic enzymes and bilirubin, has been reported in the trials, particularly in the first month of therapy with high Cyclosporine doses. Monitoring for hepatotoxicity is crucial, especially in patients with comorbidities and confounding factors. Fatal outcomes have been reported, primarily in transplant patients.

6. Malignancies: Individuals taking Cyclosporine are at an elevated risk of developing lymphomas and other malignancies, particularly skin cancers. Avoidance of excessive ultraviolet light exposure is recommended, and the risk is associated with the intensity and duration of immunosuppression.

7. Serious Infections: Immunosuppressed patients, including those receiving Cyclosporine, are at an increased risk of infections caused by bacteria, viruses, fungi, and protozoa, including opportunistic infections. These infections may have serious, including fatal, outcomes.

8. Polyoma Virus Infections: Patients with suppressed immune systems face an elevated risk of opportunistic infections, including polyoma virus infections. Serious outcomes, such as JC virus-associated progressive multifocal leukoencephalopathy (PML) and polyoma virus-associated nephropathy (PVAN), have been observed in patients receiving Cyclosporine.

9. Neurotoxicity: Encephalopathy, including posterior reversible encephalopathy syndrome (PRES), has been described in post-marketing reports. Manifestations include impaired consciousness, convulsions, visual disturbances, loss of motor function, movement disorders, and psychiatric problems. Factors predisposing to neurotoxicity include hypertension, hypomagnesemia, hypocholesterolemia, high-dose corticosteroids, high Cyclosporine blood concentrations, and graft-versus-host disease. Changes are often reversible upon discontinuation or dose reduction of Cyclosporine, particularly in liver transplant patients. Optic disc edema, including papilloedema, with potential visual impairment, has been reported, primarily in transplant patients.

10. Rheumatoid Arthritis: In rheumatoid arthritis patients, Cyclosporine nephropathy was detected in renal biopsies of 10 percent of patients after an average treatment duration of 19 months. A higher risk of malignant lymphomas is associated with Cyclosporine use.

11. Renal Function: The risks of nephrotoxicity and hypertension rise with increased doses and prolonged therapy, particularly in individuals with impaired renal function, uncontrolled hypertension, or malignancies. Renal function must be closely monitored, and caution is advised regarding sun exposure. Psoriasis patients treated with Cyclosporine capsules are at increased risk of skin and lymphoproliferative malignancies. The relative risk is similar to what is seen in psoriasis patients treated with alternative immunosuppressive agents.

12. Special Excipients: The alcohol content of Cyclosporine should be considered, especially in patients where alcohol intake should be minimized. For an adult weighing 154 pounds, the maximum daily oral dose delivers approximately six percent of the amount of alcohol in a standard drink. Special attention is needed for patients such as pregnant or breastfeeding women, those with liver disease or epilepsy, alcoholics, or pediatric patients.

The precautions associated with Cyclosporine treatment are

1. General Precautions:

Hypertension: Cyclosporine commonly induces hypertension, with mild or moderate cases being more frequent than severe ones. Antihypertensive therapy may be necessary, but caution is needed with potassium-sparing diuretics due to the potential for hyperkalemia. Calcium antagonists can be effective but may interfere with Cyclosporine metabolism.
Vaccination: During Cyclosporine treatment, vaccination may be less effective, and live attenuated vaccines should be avoided.

2. Prescribing Warning: Cyclosporine, a systemic immunosuppressant, must be prescribed by experienced physicians familiar with managing immunosuppressive therapy. Specialized care is essential for solid organ transplantation doses.

3. Facility Needs: Patients on Cyclosporine require management in well-equipped facilities with adequate medical resources. The responsible physician should possess detailed patient follow-up information.

4. Immunosuppression Risks: Cyclosporine elevates infection susceptibility and neoplasia development, especially in transplant patients receiving other immunosuppressive agents.

5. Bioavailability Variation: Cyclosporine is not interchangeable without physician oversight. Cyclosporine has a higher bioavailability, impacting Cyclosporine blood concentrations. Monitoring is crucial for transplant and rheumatoid arthritis patients to prevent toxicity or rejection.

6. Special Monitoring for Rheumatoid Arthritis Patients: Before starting treatment, blood pressure and creatinine levels should be assessed, and regular monitoring should be performed during the initial months. If hypertension occurs, consider dose reduction or antihypertensive agents.

7. Special Monitoring for Psoriasis Patients: Conduct a thorough dermatological and physical examination before treatment initiation. Monitor blood pressure, serum creatinine, and other lab values regularly. Low starting doses and careful monitoring help reduce the risk of Cyclosporine nephropathy.

9. Laboratory Tests: Regularly assess renal and liver functions, serum lipids, magnesium, potassium, and Cyclosporine blood concentrations in all patients treated with Cyclosporine. Routine blood concentration monitoring is essential for transplant patients.

What Are the Drug Interactions of Cyclosporine Capsules?

1. Drugs Potentiating Renal Dysfunction:

NSAIDs.
Antibiotics (Entamicin, Vancomycin).
Antifungals (Ketoconazole, Fluconazole).
Immunosuppressives (Tacrolimus, Mycophenolate).

2. Drugs Increasing Cyclosporine Concentrations:

Calcium Channel Blockers (Diltiazem, Verapamil).
Antifungals (Itraconazole, Voriconazole).
Antibiotics (Clarithromycin, Erythromycin).
Glucocorticoids (Methylprednisolone).
Other drugs (Amiodarone, Colchicine).

3. Drugs Decreasing Cyclosporine Concentrations:

Antibiotics (Rifampin, Nafcillin).
Anticonvulsants (Carbamazepine, Phenytoin).
Other drugs (Bosentan, St. John’s Wort).

4. Specific Drug Interactions:

Bosentan.
Boceprevir and Telaprevir.
Grapefruit juice.

5. Drugs Affected by Cyclosporine:

Digoxin.
Colchicine.
Statins (Lovastatin, Simvastatin).
Repaglinide.
Ambrisentan.
Anthracycline antibiotics (Doxorubicin).

6. Other Considerations:

Sirolimus.
Nifedipine.
Methotrexate.
Potassium-sparing diuretics.
NSAIDs (Naproxen, Sulindac).
Immunosuppressive agents and radiation in psoriasis treatment.

Specific Considerations:

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Cyclosporine, a Pregnancy Category C drug, showed potential reproductive toxicity in animal studies. Malignancy risk increases with immunosuppression. Psoriasis patients on Cyclosporine reported malignancies, emphasizing the need for caution.
Pregnancy: Cyclosporine poses risks in animal studies, and limited human data suggest potential adverse effects on pregnancy outcomes. The decision to use Cyclosporine during pregnancy should weigh the risks and benefits carefully.
Nursing Mothers: Cyclosporine is detectable in breast milk. Because of the adverse reactions in breastfeeding infants (breastfeeding), discontinuation of nursing or the drug should be considered.
Pediatric Use: Although used in transplant recipients as young as one year, the safety and effectiveness of Cyclosporine in individuals under the age of 18 with juvenile rheumatoid arthritis or psoriasis have not been established.
Geriatric Use: Elderly patients (65 and older) may exhibit hypertension and serum creatinine rises. Dose selection should be cautious, considering potential organ function declines and comorbidities.

Are There Alternatives to Cyclosporine?

While Cyclosporine is a cornerstone of immunosuppressive therapy, alternatives may be considered depending on the condition:

Tacrolimus: Often used for organ transplant recipients with fewer side effects.

Methotrexate: A common alternative for autoimmune diseases like rheumatoid arthritis.

Biologic Agents: Drugs such as Adalimumab and etanercept target specific immune pathways in autoimmune disorders.

Cyclosporine Capsules: Dosage, Indications, Contraindications, and Side Effects